Europe Cancer Vaccines Market

Europe Cancer Vaccines Market

  • HC-1083
  • 4.3 Rating
  • 160 Pages
  • Upcoming
  • 85 Reviews
  • PDF Excel PPT
raksha

Author :

Raksha Sharma

Vineet

Fact-checked by :

Vineet Pandey

Vishal

Editor :

Vishal Golekar

Europe Cancer Vaccines Market Outlook 2031

The Europe cancer vaccines market size was USD 2.20 Billion in 2022 and is estimated to reach USD 8.90 Billion by 2031 expand at a significant CAGR of 16.8% during the forecast period, 2023–2031. The growth of the market is attributed to the rising number of cancer cases, as well as scientific advancements in cancer vaccinations, along with massive cancer-care costs.

Cancer vaccines are considered vaccines that are designed to improve the body's natural immune response to cancer to avoid or treat cancer. Biological response regulators are drugs including cancer vaccinations. These biological response modifiers help the body's immune system to combat cancer by boosting it.

Europe Cancer Vaccines Market Outlook

Cancer vaccines are divided into two categories: therapeutic cancer vaccines and preventive cancer vaccines. Preventive cancer vaccinations are given to normal people to help them avert cancer. Cancer patients are given therapeutic cancer vaccines to boost their immune system's ability combat the disease. Cancer vaccinations can be given intravenously to both adults and children.

Furthermore, owing to a large number of cancer cases and the negative impacts of current medications, healthcare professionals are seeking alternative remedies.

Europe Cancer Vaccines Market Trends, Drivers, Restraints, and Opportunities

  • Smoking, liquor, and poor eating habits are key risk factors for rising cancer cases, are projected to spur the market growth during the forecast period.
  • Increasing medication research in the field of cancer, government assistance, growing elderly population, growing medical services and investments, increasing awareness of cancer rates, and existing treatments are major factors pushing the market expansion in the coming years.
  • High cost of cancer vaccines and the extended period needed to make a single vaccine are estimated to hinder the market growth.
  • Shortages of cancer vaccines in remote areas, as well as the need for cold handling and distribution, possess as main challenges that can restrict the market expansion in the coming years.
  • Removal of regulations and the resumption of R&D projects and clinical studies for cancer vaccines are expected to offer lucrative opportunities for the market players.

Scope of The Europe Cancer Vaccines Market Report

The report on the Europe cancer vaccines market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Cancer Vaccines Market - Europe Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Technologies (Viral Vector and DNA Cancer Vaccines, Whole-cell Cancer Vaccines, Recombinant Cancer Vaccines, and Others), Treatment Methods (Therapeutic Vaccines and Preventive Vaccines), and Applications (Cervical Cancer, Prostate Cancer, and Others)

Geographies

United Kingdom, Germany, France, Spain, Italy, and the Rest of Europe

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Amgen Inc.; Sanofi SA; Aduro Biotech, Inc.; Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC); Bristol-Myers Squibb; GlaxoSmithKline PLC; Merck & Co. Inc.; and OSE Immunotherapeutics

Europe Cancer Vaccines Market Segment Insights

Recombinant cancer vaccines segment is projected to constitute a major market share

Based on technologies, the Europe cancer vaccines market is divided into viral vector and DNA cancer vaccines, whole-cell cancer vaccines, recombinant cancer vaccines, and others. The recombinant cancer vaccines segment is expected to hold a key share of the market during the forecast period owing to the increasing use of recombinant technology, increased use of recombinant vaccines, and a rise in the number of licensed cancer vaccines produced utilizing recombinant technology are all driving the segment's growth.

Europe Cancer Vaccines Market Technologies

Preventive vaccines segment is expected to grow at a robust pace

On the basis of treatment methods, the market is segmented into therapeutic vaccines and preventive vaccines. The preventive vaccines segment is expected to account for a key share of the market in the coming years due to vaccinations aimed at preventing cancer in healthy persons are known as preventive or prophylactic vaccines.

These vaccinations function by protecting against infectious pathogens that can potentially contribute to cancer. Gardasil 9, Gardasil, and Cervarix vaccinations have been licensed by the European Medical Authority to prevent people from cervical cancer as well as other HPV-related malignancies and pre-cancerous disorders.

Cervical cancer segment is anticipated to expand at a rapid CAGR

In terms of applications, the Europe cancer vaccines market is segregated into cervical cancer, prostate cancer, and others. The cervical cancer segment is expected to constitute a key share of the market during the forecast period owing to the higher incidence of cervical cancer and the rising number of individuals infected with the human papillomavirus (HPV).

Furthermore, the segment's expansion is fueled by a growth in the elderly people, therapeutic innovation in the field of cervical cancer, and increased patient knowledge of the disease.

Europe Cancer Vaccines Market Applications

Spain is anticipated to dominate the market

On the basis of geographies, the market is categorized as United Kingdom, Germany, France, Spain, Italy, and the Rest of Europe. Spain is anticipated to expand at a healthy CAGR during the forecast period. The market growth can be attributed to the patient awareness of cancer treatment is increasing, as is the use of cancer vaccines in combination with other medicines and the rise in cancer patients.

Segments


The Europe cancer vaccines market has been segmented based on

Technologies

  • Viral Vector and DNA Cancer Vaccines
  • Whole-cell Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Others

Treatment Methods

  • Therapeutic Vaccines
  • Preventive Vaccines

Applications

  • Cervical Cancer
  • Prostate Cancer
  • Others

Geographies

  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy
  • the Rest of Europe

Key Players

  • Amgen Inc.
  • Sanofi SA
  • Aduro Biotech, Inc.
  • Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC)
  • Bristol-Myers Squibb
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • OSE Immunotherapeutics

Competitive Landscape

Key players competing in the Europe cancer vaccines market include Amgen Inc.; Sanofi SA; Aduro Biotech, Inc.; Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC); Bristol-Myers Squibb; GlaxoSmithKline PLC; Merck & Co. Inc.; and OSE Immunotherapeutics. Some of these players are adopting several business strategies such as acquisitions, mergers, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares.

Europe Cancer Vaccines Market Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cancer Vaccines Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cancer Vaccines Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cancer Vaccines Market - Supply Chain
  4.5. Global Cancer Vaccines Market Forecast
     4.5.1. Cancer Vaccines Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cancer Vaccines Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cancer Vaccines Market Absolute $ Opportunity
5. Global Cancer Vaccines Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Cancer Vaccines Market Size and Volume Forecast by Applications
     5.3.1. Cervical Cancer Prostate Cancer Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Cancer Vaccines Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Cancer Vaccines Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Cancer Vaccines Demand Share Forecast, 2019-2026
7. North America Cancer Vaccines Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Cancer Vaccines Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Cancer Vaccines Market Size and Volume Forecast by Applications
     7.4.1. Cervical Cancer Prostate Cancer Others
  7.5. Basis Point Share (BPS) Analysis by Applications
  7.6. Y-o-Y Growth Projections by Applications
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Cancer Vaccines Demand Share Forecast, 2019-2026
8. Latin America Cancer Vaccines Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Cancer Vaccines Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Cancer Vaccines Market Size and Volume Forecast by Applications
     8.4.1. Cervical Cancer Prostate Cancer Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Cancer Vaccines Demand Share Forecast, 2019-2026
9. Europe Cancer Vaccines Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Cancer Vaccines Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Cancer Vaccines Market Size and Volume Forecast by Applications
     9.4.1. Cervical Cancer Prostate Cancer Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Cancer Vaccines Demand Share Forecast, 2019-2026
10. Asia Pacific Cancer Vaccines Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Cancer Vaccines Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Cancer Vaccines Market Size and Volume Forecast by Applications
     10.4.1. Cervical Cancer Prostate Cancer Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Cancer Vaccines Demand Share Forecast, 2019-2026
11. Middle East & Africa Cancer Vaccines Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Cancer Vaccines Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Cancer Vaccines Market Size and Volume Forecast by Applications
     11.4.1. Cervical Cancer Prostate Cancer Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Cancer Vaccines Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Cancer Vaccines Market: Market Share Analysis
  12.2. Cancer Vaccines Distributors and Customers
  12.3. Cancer Vaccines Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Amgen Inc.
     12.4.2. Sanofi SA
     12.4.3. Aduro Biotech, Inc.
     12.4.4. Sanpower Group Co., Ltd.(Dendreon Pharmaceuticals LLC)
     12.4.5. Bristol-Myers Squib

Purchase Premium Report